Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Breast Neoplasms 7Lymphoma 6Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 4Neuroblastoma 3Lymphoma, Large-Cell, Anaplastic 3Leukemia, Myeloid, Acute 3Immunoblastic Lymphadenopathy 3Head and Neck Neoplasms 3Waldenstrom Macroglobulinemia 2Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumors 2

Interventions

Doxorubicin 13Gemcitabine 10Ifosfamide 9Trabectedin 7Radiotherapy 7Docetaxel 5Dacarbazine 5pazopanib 3Sunitinib 3Sorafenib 3Nivolumab 3Filgrastim 3pembrolizumab 2pegfilgrastim 2liposomal doxorubicin 2eribulin 2cixutumumab 2belinostat 2Radiotherapy, Conformal 2Imatinib Mesylate 2Chemotherapy, Adjuvant 2Bevacizumab 2tremelimumab 1temsirolimus 1soblidotin 1selinexor 1sargramostim 1saracatinib 1rubitecan 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leiomyosarcoma × MLN 8237 × Clear all
NCT01653028 2017-11-30

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡